isoxazoles has been researched along with bosentan anhydrous in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (61.02) | 29.6817 |
| 2010's | 23 (38.98) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, NH; Rubin, LJ | 1 |
| Lüscher, TF; Spieker, LE | 1 |
| McLaughlin, VV; Rich, S | 1 |
| Branzi, A; Galié, N; Manes, A | 1 |
| Wilkins, MR | 1 |
| Cheng, J; Liu, C | 1 |
| Channick, RN; Lee, SH | 1 |
| Badesch, D; Barst, RJ; Frost, A; Galie, N; Langleben, D; Lawrence, EC; Naeije, R; Shapiro, S | 1 |
| Archer, SL; Michelakis, ED | 1 |
| Abman, SH | 1 |
| Coyne, TC | 1 |
| Ewert, R; Opitz, CF | 1 |
| Hoeper, MM | 1 |
| Barst, RJ; Benza, RL; Keogh, A; Lawrence, EC; Mehta, S; Oudiz, RJ | 1 |
| Langleben, D | 1 |
| Baloira, A | 1 |
| Dhaun, N; Goddard, J; Pollock, DM; Webb, DJ | 1 |
| Dinh-Xuan, AT; Hoeper, MM | 1 |
| Dupuis, J; Hoeper, MM | 1 |
| Amoura, Z; Cacoub, P; Langleben, D | 1 |
| Batyraliev, TA; Ekinsi, E; Makhmutkhodzhaev, SA; Pataraia, SA; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA | 1 |
| Park, MH | 1 |
| Howard, LS; Price, LC | 1 |
| Ewert, R; Kirch, W; Opitz, CF; Pittrow, D | 1 |
| Coghlan, G; Kabunga, P | 1 |
| Badesch, DB; Despain, DJ; Dufton, C; Frost, AE; Galie, N; Gerber, MJ; McGoon, MD; McLaughlin, VV; Olschewski, H; Oudiz, RJ; Rubin, LJ | 1 |
| Stähler, G | 1 |
| Book, WM; Lee, EK; Lyle, TA; McConnell, ME; Mehta, PK; Simpson, L | 1 |
| Faruqi, S; Fathi, H; Morice, AH | 1 |
| Champion, HC; Girgis, RE; Hassoun, PM; Hummers, LK; Mathai, SC; Wigley, FM; Zaiman, A | 1 |
| Preston, IR; Steiner, MK | 1 |
| Beghetti, M; Galiè, N | 1 |
| Cacoub, P; Langleben, D | 1 |
| Mucke, HA | 1 |
| Dranitsaris, G; Mehta, S | 1 |
| Ghofrani, HA | 1 |
| Barton, P; Chen, YF; Fry-Smith, A; Gibbs, JS; Hyde, C; Jowett, S; Malottki, K; Moore, D; Pepke-Zaba, J; Roberts, J | 1 |
| Corris, PA; Langleben, D | 1 |
| Dalton, B; Gabbay, E; Keogh, A; Steele, P; Stewart, S; Strange, G; Wlodarczyk, J | 1 |
| Humbert, M; Montani, D | 1 |
| Hunsche, E; Lefebvre, MC | 1 |
| Dhaun, N; Goddard, J; Lilitkarntakul, P; MacIntyre, IM; Melville, V; Webb, DJ | 1 |
| Brouwer, K; Gorczynski, R; Hartman, JC; Mandagere, A; Melvin, L | 1 |
| Coghlan, JG; Denton, CP; Handler, CE; Kabunga, P; Smith, CJ; Valerio, CJ | 1 |
| Krause, G; Lättig, J | 1 |
| Derk, CT; Shetty, N | 1 |
| Bauleo, C; Catapano, G; Formichi, B; Genovesi, D; Giuntini, C; Mannucci, F; Marini, C; Michelassi, C; Monti, S; Prediletto, R | 1 |
| French, B; Gabler, NB; Halpern, SD; Kawut, SM; Liu, Z; Palevsky, HI; Strom, BL; Taichman, DB | 1 |
| Arnaud, C; Blaise, S; Boutonnat, J; Cracowski, JL; Dufournet, B; Godin-Ribuot, D; Hellmann, M; Millet, C; Ribuot, C; Roustit, M | 1 |
| Guzik, T; Kopeć, G; Mikołajczyk, T; Miszalski-Jamka, T; Podolec, P; Tyrka, A; Waligóra, M | 1 |
| Blenkhorn, F; Eisenberg, MJ; Fox, B; Hirsch, AM; Joyal, D; Langleben, D; Lesenko, L; Schlesinger, RD | 1 |
| Luo, N; Ryan, JJ | 1 |
| Celermajer, DS; Corte, TJ; Don, GW; Joseph, F | 1 |
| Brizzolara, R; Cutolo, M; Ferrone, C; Montagna, P; Parodio, A; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B | 1 |
| Catalá-López, F; de la Fuente Honrubia, C; Macías Saint-Gerons, D; Montero Corominas, D | 1 |
| Barbaro Foschino, MP; Brunetti, ND; Correale, M; Di Biase, M; Lacedonia, D; Montrone, D; Totaro, A | 1 |
| Brouwer, KR; Gillies, H; Hao, J; Hubert, C; Lepist, EI; Ray, AS; Smith, W; St Claire, RL | 1 |
| Benza, RL; Dhaun, N; Hwang, LJ; Liu, X; Naeije, R; Teal, S; Vachiery, JL; Webb, DJ | 1 |
| Andersson, LC; Bergare, J; Billger, M; Eakins, JA; Elebring, M; Elmore, CS; Foster, AJ; Kenna, JG; Stahl, SH; Thompson, RA | 1 |
29 review(s) available for isoxazoles and bosentan anhydrous
| Article | Year |
|---|---|
Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Pulmonary Artery; Sulfonamides; Thiophenes | 2002 |
Will endothelin receptor antagonists have a role in heart failure?
Topics: Animals; Bosentan; Cardiovascular Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Isoxazoles; Oligopeptides; Peptides, Cyclic; Phenylpropionates; Piperidines; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Thiophenes; Treatment Outcome | 2003 |
Endothelin receptor blockers in cardiovascular disease.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiovascular Diseases; Endothelin Receptor Antagonists; Exercise Tolerance; Hemodynamics; Humans; Isoxazoles; Sulfonamides; Thiophenes | 2003 |
The endothelin system in pulmonary arterial hypertension.
Topics: Animals; Bosentan; Endothelial Cells; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Infant, Newborn; Isoxazoles; Models, Animal; Muscle, Smooth, Vascular; Pulmonary Circulation; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Thiophenes | 2004 |
Endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Child; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes | 2005 |
Endothelin antagonism in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Piperazines; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2005 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic Acid; Drug Therapy, Combination; Epoprostenol; Evidence-Based Medicine; Fluoxetine; Humans; Hypertension, Pulmonary; Iloprost; Imatinib Mesylate; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Pulmonary Artery; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Simvastatin; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2006 |
Pulmonary hypertension in older children: new approaches and therapies.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Cardiac Catheterization; Child; Cyclic Nucleotide Phosphodiesterases, Type 5; Echocardiography; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Phosphodiesterase Inhibitors; Pulmonary Wedge Pressure; Sulfonamides; Thiophenes; Treatment Outcome | 2006 |
Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cell Division; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Isoxazoles; Lung; Pulmonary Fibrosis; Sulfonamides; Thiophenes; Vasoconstriction; Vasodilation | 2006 |
[Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Drug Interactions; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Survival Rate; Thiophenes | 2006 |
Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes | 2007 |
Selective and mixed endothelin receptor antagonism in cardiovascular disease.
Topics: Animals; Bosentan; Clinical Trials as Topic; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Models, Biological; Sulfonamides; Thiophenes | 2007 |
Endothelin receptor antagonists in pulmonary arterial hypertension.
Topics: Animals; Bosentan; Clinical Trials, Phase III as Topic; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Severity of Illness Index; Sulfonamides; Survival Rate; Thiophenes; Treatment Outcome | 2008 |
[Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2008 |
[Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes; Ventricular Dysfunction, Right | 2007 |
Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasoconstriction | 2008 |
Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials, Phase III as Topic; Drug Interactions; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2008 |
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Phenylpropionates; Pulmonary Artery; Pyridazines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes; Treatment Outcome; Vascular Resistance; Walking | 2008 |
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
[Specific drugs for the treatment of pulmonary arterial hypertension - current status].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2008 |
Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Patient Compliance; Patient Satisfaction; Phenylpropionates; Pyridazines; Quality of Life; Receptors, Endothelin; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2009 |
Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Design; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Patents as Topic; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2009 |
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; United States; Vasodilator Agents | 2009 |
Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cohort Studies; Epoprostenol; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Time Factors; Treatment Outcome | 2010 |
[Causes of selectivity, activation and inhibition. Molecular mechanisms of endothelin-receptor recognition].
Topics: Amino Acid Sequence; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Isoxazoles; Ligands; Models, Molecular; Molecular Sequence Data; Receptors, Endothelin; Sulfonamides; Thiophenes | 2010 |
Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Familial Primary Pulmonary Hypertension; Fibrosis; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2011 |
[Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
Topics: Antihypertensive Agents; Biomarkers; Bosentan; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Humans; Hypertension; Isoxazoles; Phenylpropionates; Pyridazines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Thiophenes; Transaminases | 2014 |
Novelty in treatment of pulmonary fibrosis: pulmonary hypertension drugs and others.
Topics: Antihypertensive Agents; Bosentan; Humans; Isoxazoles; Phenylpropionates; Phosphodiesterase Inhibitors; Pulmonary Fibrosis; Pyridazines; Sulfonamides; Thiophenes | 2013 |
8 trial(s) available for isoxazoles and bosentan anhydrous
| Article | Year |
|---|---|
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Endothelin A Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Health Status Indicators; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Risk Assessment; Sulfonamides; Thiophenes; Treatment Outcome | 2006 |
Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Sulfonamides; Thiophenes; Treatment Outcome | 2007 |
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Child; Disease-Free Survival; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver Function Tests; Male; Middle Aged; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes; Transaminases; Treatment Outcome; Young Adult | 2009 |
Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
Topics: Administration, Oral; Adult; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Bosentan; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endothelin A Receptor Antagonists; Endothelin-1; Humans; Isoxazoles; Male; Middle Aged; Plethysmography; Probability; Receptor, Endothelin A; Reference Values; Sulfonamides; Thiophenes; Young Adult | 2010 |
Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Ethnicity; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Phenylpropionates; Prevalence; Prospective Studies; Pulmonary Wedge Pressure; Pyridazines; Sex Factors; Sulfonamides; Thiophenes; Treatment Outcome; United States; Walking; Young Adult | 2012 |
Iontophoresis of endothelin receptor antagonists in rats and men.
Topics: Adolescent; Adult; Aged; Animals; Blood Pressure; Bosentan; Electrodes; Endothelin Receptor Antagonists; Endothelins; Humans; Iontophoresis; Isoxazoles; Male; Middle Aged; Rats; Rats, Wistar; Receptors, Endothelin; Regional Blood Flow; Skin; Sulfonamides; Thiophenes; Young Adult | 2012 |
Changes in exercise capacity and cardiac performance in a series of patients with Eisenmenger's syndrome transitioned from selective to dual endothelin receptor antagonist.
Topics: Adult; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Endothelin-1; Exercise; Female; Follow-Up Studies; Humans; Isoxazoles; Magnetic Resonance Imaging; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Sulfonamides; Thiophenes | 2012 |
Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bosentan; Child; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Prospective Studies; Sulfonamides; Survival Rate; Thiophenes; Time Factors; Treatment Outcome; United States; Uric Acid; Young Adult | 2014 |
22 other study(ies) available for isoxazoles and bosentan anhydrous
| Article | Year |
|---|---|
Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Humans; Hypertension, Pulmonary; Isoxazoles; Sulfonamides; Thiophenes | 2004 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Disease Management; Drug Interactions; Endothelin Receptor Antagonists; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Isoxazoles; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents; Walking | 2006 |
[Pulmonary hypertension treatment: future prospects].
Topics: Administration, Intranasal; Administration, Oral; Animals; Bosentan; Drug Evaluation, Preclinical; Endothelin A Receptor Antagonists; Epoprostenol; Forecasting; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Isoxazoles; Life Expectancy; Lung Transplantation; Monocrotaline; Piperazines; Platelet-Derived Growth Factor; Purines; Randomized Controlled Trials as Topic; Rats; Sheep; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2007 |
Pulmonary hypertension: basic concepts and practical management.
Topics: Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Receptors, Endothelin; Sensitivity and Specificity; Sulfonamides; Survival Analysis; Thiophenes; Treatment Outcome | 2008 |
Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Eisenmenger Complex; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Exercise Test; Female; Heart Defects, Congenital; Humans; Isoxazoles; Male; Middle Aged; Oxygen; Retrospective Studies; Sulfonamides; Thiophenes | 2008 |
Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
Topics: Adult; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Sulfonamides; Tadalafil; Thiophenes; Treatment Outcome; Vasodilator Agents | 2010 |
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Topics: Bosentan; Cohort Studies; Comorbidity; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Lung Diseases, Interstitial; Male; Maryland; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Purines; Receptors, Endothelin; Scleroderma, Diffuse; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2009 |
A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Thiophenes; Transaminases; Treatment Outcome | 2009 |
Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Canada; Costs and Cost Analysis; Drug Costs; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Piperazines; Placebos; Purines; Pyridazines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Treatment Outcome | 2009 |
[Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Cell Proliferation; Endothelial Cells; Endothelin Receptor Antagonists; Endothelium, Vascular; Humans; Hypertension, Pulmonary; Isoxazoles; Sulfonamides; Thiophenes; Vasoconstriction; Vasodilation | 2009 |
The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Phenotype; Receptors, Endothelin; Sulfonamides; Thiophenes | 2010 |
[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Europe; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Practice Guidelines as Topic; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2010 |
Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Canada; Cost Control; Drug Costs; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2010 |
Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Bosentan; Cell Culture Techniques; Cells, Cultured; Endothelin Receptor Antagonists; Enkephalin, D-Penicillamine (2,5)-; Estradiol; Female; Hepatocytes; Humans; Isoxazoles; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Phenylpropionates; Pyridazines; Pyrimidines; Sulfonamides; Symporters; Taurocholic Acid; Thiophenes; Young Adult | 2010 |
Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
Topics: Aged; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Connective Tissue Diseases; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Statistics as Topic; Sulfonamides; Thiophenes; Treatment Outcome | 2010 |
Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension.
Topics: Acid-Base Equilibrium; Aged; Antihypertensive Agents; Blood Gas Analysis; Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Oxygen Consumption; Oxygen Inhalation Therapy; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Thromboembolism; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2013 |
Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Middle Aged; Phenylpropionates; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sulfonamides; Thiophenes; Treatment Outcome; Vascular Resistance | 2013 |
Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
Topics: Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pulmonary Wedge Pressure; Pyridazines; Sulfonamides; Thiophenes; Vascular Resistance | 2013 |
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Liver Function Tests; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Safety-Based Drug Withdrawals; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2012 |
Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients.
Topics: Aged; Bosentan; Cells, Cultured; Collagen Type I; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Extracellular Matrix Proteins; Female; Fibrillin-1; Fibrillins; Fibroblasts; Fibronectins; Fibrosis; Humans; Isoxazoles; Microfilament Proteins; Middle Aged; Primary Cell Culture; Scleroderma, Systemic; Sulfonamides; Thiophenes | 2012 |
Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Bile Acids and Salts; Bosentan; Endothelin Receptor Antagonists; Female; Hepatocytes; Humans; Isoxazoles; Liver; Liver-Specific Organic Anion Transporter 1; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Organic Anion Transporters, Sodium-Independent; Phenylpropionates; Pyridazines; Pyrimidines; Receptors, Endothelin; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Symporters; Taurocholic Acid; Thiophenes | 2014 |
Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Bosentan; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Epithelial Cells; Hepatocytes; Humans; Isoxazoles; Mitochondria; Molecular Structure; Oxygen Consumption; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2015 |